Comparing of Different Biomarkers From Vena Rectalis Superior and Vena Cubiti in Patients Undergoing Low Anterior Resection for Rectum Cancer
|ClinicalTrials.gov Identifier: NCT01706809|
Recruitment Status : Unknown
Verified February 2014 by Mark Ellebaek Pedersen, Odense University Hospital.
Recruitment status was: Recruiting
First Posted : October 15, 2012
Last Update Posted : February 5, 2014
|Condition or disease||Intervention/treatment|
|Rectal Cancer||Other: blood sampels from vena rectalis superior and vena cubiti|
Patients undergoing LAR for rectum cancer is subjected. Preoperative blood samples from vena rectalis superior and vena cubiti is collected, as well as biopsies from tumor. Preoperative and after 3 month peripheral blood samples is collected.
A total of 50 patients will be included in this study.
The study is approved by the local scientific ethical committee No. S-20100006
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Observational Model:||Case Control|
|Study Start Date :||September 2011|
|Estimated Primary Completion Date :||September 2015|
|Estimated Study Completion Date :||December 2015|
|Biomarkeres||Other: blood sampels from vena rectalis superior and vena cubiti|
- The primary aim of the present study is to investigate different biomarkers like VEGF, EVGF and others ability to predict time to recidive and progressions free survival. [ Time Frame: after the study is complete ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01706809
|Vejle, Denmark, 5000|
|Contact: Hans Rahr, MD 7940 5600 ext 0045 email@example.com|